Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Phillip Maples, Catherine Moukheibir

Premium

Gradalis has promoted Phillip Maples as executive vice president and chief technical officer.

Maples joined the company as its first employee in 2005, and in his new role will continue to oversee product development, manufacturing, and quality assurance.

Before Gradalis, Maples held various roles at Baxter Healthcare, US Oncology, and CellExSys.


Therapeutic protein developer Ablnyx has appointed Catherine Moukheibir it is board of directors.

Moukheibir is currently a board member of Innate Pharma and an independent director of Creabilis. She previously served as vice president of Spanish RNAi drug developer Sylentis.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.